Vivos Therapeutics Inc. Common Stock (VVOS)
Stock · NASDAQ · Health Care
$0.1292as of 10/16/2026
Price chart
Active signals
VVOS Signal Track Record
How signals performed across all stocks →What VVOS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -11.4% | 34% | September 29, 2026 |
| Bollinger Band BreakdownActive now | 22 | -9.6% | 32% | September 28, 2026 |
| Bollinger Band Breakout | 17 | -26.7% | 41% | June 5, 2026 |
| Any 20-session window (baseline) | -13.4% | 28% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VVOS
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snor…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 268
- Website
- vivos.com/
Fundamentals
- 1-day range
- $0.1283$0.1427
- Market cap
- $4.47M
- P/E (trailing)
- —
- P/E (forward)
- -0.16
- EPS (trailing)
- $-1.88
- Dividend yield
- —
- Beta
- 6.44
- Avg. volume
- 13.11M
How Vivos Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Apr 15, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Vivos Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VVOSVivos Therapeutics Inc. Common Stock$0.131▼ 8.39%Market cap $4.47MP/E —$0.1276$3.28
- GCTKGlucoTrack Inc. Common Stock$0.725▼ 12.86%Market cap $4.25MP/E 0.07$1.77$136.29
- INBSIntelligent Bio Solutions Inc. Common Stock$1.5▲ 4.17%Market cap $4.76MP/E —$1.35$24.9
- XAIRBeyond Air Inc. Common Stock$2.16▼ 2.26%Market cap $4.93MP/E —$2.31$55.6
- NXGLNexGel Inc Common Stock$5.59▲ 7.92%Market cap $3.13MP/E —$3$57
- SNOASonoma Pharmaceuticals Inc. Common Stock$1.12▼ 2.61%Market cap $5.99MP/E —$0.8501$4.25
- IVFINVO Fertility Inc. Common Stock$0.558▼ 5.58%Market cap $2.39MP/E —$0.58$84.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VVOS Vivos Therapeutics Inc. Common Stock | $4.47M | — | $0.131 | ▼ 8.39% | $0.1276$3.28 |
| GCTK GlucoTrack Inc. Common Stock | $4.25M | 0.07 | $0.725 | ▼ 12.86% | $1.77$136.29 |
| INBS Intelligent Bio Solutions Inc. Common Stock | $4.76M | — | $1.5 | ▲ 4.17% | $1.35$24.9 |
| XAIR Beyond Air Inc. Common Stock | $4.93M | — | $2.16 | ▼ 2.26% | $2.31$55.6 |
| NXGL NexGel Inc Common Stock | $3.13M | — | $5.59 | ▲ 7.92% | $3$57 |
| SNOA Sonoma Pharmaceuticals Inc. Common Stock | $5.99M | — | $1.12 | ▼ 2.61% | $0.8501$4.25 |
| IVF INVO Fertility Inc. Common Stock | $2.39M | — | $0.558 | ▼ 5.58% | $0.58$84.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12Mbenzinga · 10/15/2026
- Most active stocks in Tuesday's sessionChartMill · 9/29/2026
- Vivos Therapeutics Targets $3.6 Million in Annual Cost Reductions as Revenue Growth Initiatives AccelerateYahoo · 9/29/2026
- Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth InitiativesYahoo · 9/29/2026
- Vivos Therapeutics Announces Restructuring And Cost Reduction Plan With An Annual Savings Target Of $3.6M From Q4 2026Benzinga · 9/29/2026
Insider Activity
Insider Actions →- Leonard J. Sokolow · September 14, 2026 · Grant12.0K
- Gregg C. Johnson · September 14, 2026 · Grant12.0K
- Amman Bradford K. · July 31, 2026 · Grant150.0K @ $0.41
- Amman Bradford K. · July 31, 2026 · Grant250.0K @ $0.41
- Skaff Michael C · June 30, 2026 · Buy1.89M @ $0.582
- Huntsman Ronald Kirk · June 30, 2026 · J85.9K @ $0.582
- Skaff Michael C · June 30, 2026 · Buy2.75M @ $0.582
- Skaff Michael C · June 30, 2026 · Buy859.2K @ $0.582
Institutional Ownership
March 31, 2026
- Total shares held
- 1.55M
- Total value held
- $1.82M
- Institutional holders
- 23
- Unknown1.12M
- Unknown95.5K
- Unknown42.5K
- Unknown41.1K
- Unknown38.1K
- Unknown35.7K
- Unknown30.8K
- Unknown27.8K
- Unknown25.1K
- Unknown24.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
VVOS Announces $3.6M Annual Cost‑Reduction Plan
Vivos Therapeutics disclosed a restructuring plan that aims to cut annual costs by $3.6 million beginning in the fourth quarter of 2026. The company also reported progress on material cost reductions and initiatives to grow revenue. These actions are intended to improve financial efficiency while supporting ongoing growth efforts.
VVOS Announces $3.6M Annual Cost‑Reduction Plan. Vivos Therapeutics disclosed a restructuring plan that aims to cut annual costs by $3.6 million beginning in the fourth quarter of 2026. The company also reported progress on material cost reductions and initiatives to grow revenue. These actions are intended to improve financial efficiency while supporting ongoing growth efforts.